Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

NCT06478212 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

IDH1-mutant Glioma
IDH2-mutant Glioma

Interventions

DRUG: Vorasidenib
DRUG: Temozolomide (TMZ)

Sponsor

Institut de Recherches Internationales Servier